Episode
405: An obesity drug deep-dive, and peptides move mainstream
- Podcast
- The Readout Loud
- Published
- Jun 11, 2026
- Duration seconds
- 2186
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/TTSAA8579876573.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/405-an-obesity-drug-deep-dive-and-peptides-move-mainstream/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-readout-loud-1134305/405-an-obesity-drug-deep-dive-and-peptides-move-mainstream.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center). We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.